The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...
Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...
Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.
Around 55,000 new cases of prostate cancer are diagnosed in the UK every year, and super drug abiraterone will offer hope to ...
Charity hails ‘momentous’ decision to give abiraterone to about 8,000 newly diagnosed men each year ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...
What Is Akeega, and Why Does It Matter? Akeega is a dual-action tablet combining two medicines — niraparib and abiraterone acetate — that has been approved by the FDA in combination with prednisone (a ...
Life-extending prostate cancer drug to be made available to thousands more patients - Men with high-risk prostate cancer that ...
Statewide Practice Enrolling Patients in Global, Late-Phase Clinical Trial ...
Key TakeawaysNew report shows growing use of medications, such as chemotherapy, immunotherapy, and hormone therapy, given ...
The NHS has announced that the drug, abiraterone, will be offered to men with high-risk prostate cancer that has not yet ...
The NHS will provide a life-extending prostate cancer drug to men in England, expanding access to a treatment proven to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback